5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.34▼ | 1.34▼ | 1.35▼ | 1.41▼ | 1.22▲ |
MA10 | 1.34▼ | 1.35▼ | 1.37▼ | 1.37▼ | 1.34▼ |
MA20 | 1.34▼ | 1.38▼ | 1.41▼ | 1.24▲ | 1.58▼ |
MA50 | 1.36▼ | 1.43▼ | 1.40▼ | 1.34▼ | 2.11▼ |
MA100 | 1.38▼ | 1.40▼ | 1.30▲ | 1.59▼ | 2.80▼ |
MA200 | 1.41▼ | 1.29▲ | 1.23▲ | 2.03▼ | 6.93▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | -0.003▼ | -0.012▼ | 0.032▲ | 0.005▲ |
RSI | 42.973▼ | 32.035▼ | 31.536▼ | 51.783▲ | 42.518▼ |
STOCH | 50.000 | 22.298 | 20.845 | 75.607 | 32.845 |
WILL %R | -80.000▼ | -88.235▼ | -91.667▼ | -34.737 | -64.146 |
CCI | -24.863 | -109.051▼ | -97.233 | 38.262 | -17.889 |
Thursday, June 12, 2025 08:30 AM
A month has gone by since the last earnings report for Allogene Therapeutics (ALLO). Shares have added about 52.2% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
|
Wednesday, June 04, 2025 09:00 AM
Investors might want to bet on Allogene Therapeutics (ALLO), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
|
Monday, June 02, 2025 12:26 PM
Allogene Therapeutics Inc. (NASDAQ:ALLO) presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma/RCC during an oral presentation at the 2025 ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 1.35 | 1.4186 | 1.325 | 1.34 | 2,450,471 |
12/06/25 | 1.43 | 1.45 | 1.3801 | 1.40 | 2,282,726 |
11/06/25 | 1.49 | 1.50 | 1.44 | 1.45 | 2,594,726 |
10/06/25 | 1.39 | 1.505 | 1.39 | 1.47 | 2,019,331 |
09/06/25 | 1.45 | 1.50 | 1.37 | 1.41 | 2,214,437 |
06/06/25 | 1.30 | 1.47 | 1.29 | 1.42 | 3,475,881 |
05/06/25 | 1.29 | 1.33 | 1.27 | 1.29 | 1,651,780 |
04/06/25 | 1.31 | 1.355 | 1.28 | 1.29 | 1,810,538 |
03/06/25 | 1.28 | 1.37 | 1.23 | 1.35 | 2,472,224 |
02/06/25 | 1.19 | 1.37 | 1.17 | 1.27 | 6,018,054 |
|
|
||||
|
|
||||
|
|